Accelerated Approval: US FDA Panel To Reconsider Six Indications For Checkpoint Inhibitors

 
• By Sue Sutter
Time To Rethink
FDA is rethinking the accelerated approval of a host of indications for immunotherapies. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers